PURE Bioscience, Inc. (PURE)
OTCMKTS · Delayed Price · Currency is USD
0.0736
+0.0028 (3.88%)
Jul 25, 2025, 1:32 PM EDT

PURE Bioscience Cash Flow Statement

Millions USD. Fiscal year is Aug - Jul.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Apr '25 Jul '24 Jul '23 Jul '22 Jul '21 Jul '20 2016 - 2020
Net Income
-2.82-3.35-3.96-3.49-2.320
Upgrade
Depreciation & Amortization
0.040.150.120.210.170.19
Upgrade
Asset Writedown & Restructuring Costs
-0.060.320.35--
Upgrade
Stock-Based Compensation
0.160.210.320.570.840.79
Upgrade
Other Operating Activities
--0.03-0.160.15-
Upgrade
Change in Accounts Receivable
-0.05-0.01-0.080.170.72-0.72
Upgrade
Change in Inventory
-0.060.030.060.080.07-0.37
Upgrade
Change in Accounts Payable
0.310.2-0.04-0.16-0.780.77
Upgrade
Change in Other Net Operating Assets
0.280.18-0.040.01-0.02-0.01
Upgrade
Operating Cash Flow
-2.15-2.53-3.28-2.42-1.170.67
Upgrade
Capital Expenditures
---0.03-0.08-0.52-0.06
Upgrade
Investing Cash Flow
---0.03-0.08-0.52-0.06
Upgrade
Long-Term Debt Issued
-1.791.02-0.24-
Upgrade
Total Debt Issued
2.251.791.02-0.24-
Upgrade
Net Debt Issued (Repaid)
2.251.791.02-0.24-
Upgrade
Issuance of Common Stock
---3.5-2.83
Upgrade
Financing Cash Flow
2.251.791.023.50.242.83
Upgrade
Net Cash Flow
0.1-0.75-2.31-1.453.44
Upgrade
Free Cash Flow
-2.15-2.53-3.31-2.5-1.690.61
Upgrade
Free Cash Flow Margin
-112.55%-128.94%-176.40%-134.86%-42.98%8.83%
Upgrade
Free Cash Flow Per Share
-0.02-0.02-0.03-0.03-0.020.01
Upgrade
Cash Income Tax Paid
0.010.010.01000
Upgrade
Levered Free Cash Flow
-1.35-1.44-1.95-1.23-0.820.61
Upgrade
Unlevered Free Cash Flow
-1.19-1.34-1.94-1.23-0.810.62
Upgrade
Change in Net Working Capital
-0.23-0.250.08-0.18-0.140.31
Upgrade
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.